Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $10.42 -0.06 (-0.57%) (As of 09:39 AM ET) Add Compare Share Share Today's Range$10.36▼$10.4850-Day Range$10.36▼$11.6052-Week Range$8.24▼$13.24Volume105,105 shsAverage Volume6.03 million shsMarket Capitalization$7.70 billionP/E Ratio2.06Dividend YieldN/APrice Target$16.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside61.3% Upside$16.90 Price TargetShort InterestBearish7.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector585th out of 896 stocksPharmaceutical Preparations Industry271st out of 424 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.88% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Roivant Sciences has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 5 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($1.12) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.21.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. Get the name of the stock here >>> About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesJune 2, 2024 | seekingalpha.comRoivant Sciences: Executing On Huge Buyback Program With More To ComeMay 30, 2024 | investorplace.comROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024July 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.May 30, 2024 | globenewswire.comRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateMay 29, 2024 | markets.businessinsider.comRoivant Sciences is about to announce its earnings — here's what Wall Street expectsMay 29, 2024 | uk.news.yahoo.comRamaswamy Urges BuzzFeed to Cut Costs, Air Conservative VoicesMay 29, 2024 | msn.comVivek Ramaswamy pressures BuzzFeed to hire Tucker Carlson and shift to the RightMay 16, 2024 | globenewswire.comRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024July 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.May 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 1, 2024 | investorplace.com3 Healthcare Stocks With the Potential to Triple Your Investment by 2026April 25, 2024 | businesswire.comRoivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisApril 24, 2024 | seekingalpha.comRoivant Sciences: Cashing In On Vants And VenturesApril 14, 2024 | markets.businessinsider.comSunrun (RUN) Gets a Buy from RBC CapitalApril 4, 2024 | msn.comRoivant's anti-inflammatory drug shows promise in mid-stage studyApril 2, 2024 | msn.comRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease StudyApril 2, 2024 | reuters.comRoivant's anti-inflammatory drug succeeds in mid-stage studyApril 2, 2024 | globenewswire.comRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionApril 1, 2024 | msn.comCompare with CoinDesk Market Index (CDICMI)March 26, 2024 | msn.comViking Therapeutics gains on early data for oral weight loss therapyMarch 26, 2024 | msn.com'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupMarch 14, 2024 | fr.investing.comL'objectif de cours de Roivant Sciences relevé à 16$ par Goldman SachsMarch 13, 2024 | edition.cnn.comTravere Therapeutics, Inc.March 13, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)February 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive OutlookFebruary 15, 2024 | finance.yahoo.comDo You Think the Management of Roivant Sciences (ROIV) Can Create Value?February 14, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call TranscriptSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/30/2024Today7/04/2024Next Earnings (Estimated)8/12/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Target$16.90 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+61.3%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.06 Trailing P/E Ratio2.07 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.35 billion Net Margins3,484.86% Pretax Margin3,408.33% Return on Equity-25.05% Return on Assets-20.98% Debt Debt-to-Equity Ratio0.07 Current Ratio25.24 Quick Ratio25.24 Sales & Book Value Annual Sales$124.79 million Price / Sales62.04 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book1.31Miscellaneous Outstanding Shares738,720,000Free Float704,741,000Market Cap$7.74 billion OptionableOptionable Beta1.24 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Jo ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVAGenmab A/SNASDAQ:GMABBioMarin PharmaceuticalNASDAQ:BMRNRoyalty PharmaNASDAQ:RPRXSarepta TherapeuticsNASDAQ:SRPTView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 37,800 shares on 5/28/2024Ownership: 0.005%Farallon Capital Management LLCSold 6,437,400 shares on 5/24/2024Ownership: 0.112%Cetera Advisors LLCBought 71,926 shares on 5/24/2024Ownership: 0.009%Whitefort Capital Management LPBought 800,000 shares on 5/17/2024Ownership: 0.297%Ikarian Capital LLCSold 51,212 shares on 5/17/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price target for 2024? 10 Wall Street research analysts have issued 12-month target prices for Roivant Sciences' shares. Their ROIV share price targets range from $12.00 to $23.00. On average, they expect the company's share price to reach $16.90 in the next twelve months. This suggests a possible upside of 61.3% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2024? Roivant Sciences' stock was trading at $11.23 at the beginning of the year. Since then, ROIV stock has decreased by 6.7% and is now trading at $10.48. View the best growth stocks for 2024 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ROIV earnings forecast. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) posted its earnings results on Thursday, May, 30th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $28.93 million for the quarter, compared to the consensus estimate of $32.46 million. Roivant Sciences had a negative trailing twelve-month return on equity of 25.05% and a net margin of 3,484.86%. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco S&P MidCap 400 GARP ETF (GRPM), Invesco S&P MidCap 400 GARP ETF (EWMC), First Trust Health Care AlphaDEX Fund (FXH), Direxion Moonshot Innovators ETF (MOON), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU) and SPDR S&P Biotech ETF (XBI). How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredGet in before Reddit doesRobinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.